Devonian Health Group Announces Proposed Listing on the NYSE American with Concurrent Underwritten Public Offering
PR Newswire
QUÉBEC, July 27, 2026
QUÉBEC, July 27, 2026 /PRNewswire/ -- Devonian Health Group Inc. ("Devonian" or the "Company") (TSXV: GSD) (OTCQB: DVHGF), a clinical-stage biopharmaceutical company focused on developing innovative therapies targeting fibro-inflammatory diseases, today announces that it is conducting an underwritten public offering of its common shares (and/or pre-funded warrants in lieu thereof) and warrants (the "Warrants") (the "Offering"). Concurrently with the Offering, the Company expects its common shares and Warrants to be approved for listing on the NYSE American LLC (the "NYSE American") under the symbols "DHGR" and "DHGRW", respectively, subject to final authorization of the Company's listing application and continued compliance with the exchange rules. Additional details regarding the Offering will be provided through the Company's filings with the Securities and Exchange Commission (the "SEC") and those made in other filings with the applicable securities regulators of Canada. The Offering is subject to market conditions and regulatory approval, and there can be no assurance as to whether or when the Offering may be completed, or as to the actual size or terms of the Offering.
